Compare SPRU & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRU | NXTC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 24.8M |
| IPO Year | 2019 | 2019 |
| Metric | SPRU | NXTC |
|---|---|---|
| Price | $1.31 | $6.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 50.5K | ★ 63.2K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $23,194,000.00 | $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.50 | ★ N/A |
| Revenue Growth | ★ 48.68 | N/A |
| 52 Week Low | $1.29 | $1.55 |
| 52 Week High | $6.75 | $15.74 |
| Indicator | SPRU | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 54.58 |
| Support Level | N/A | $4.28 |
| Resistance Level | $2.46 | $8.68 |
| Average True Range (ATR) | 0.06 | 0.77 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 9.09 | 67.04 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.